Antibody Ingredients TRIZ Cases

Anti-CD324 antibodies reduce tumor initiating cell frequency through targeted modulation of CD324 protein pathways.

Recombinant bispecific antibody binds FLT3 and CD3 to redirect T-cells, eliminating hematopoietic stem cells while reducing conditioning toxicity.

Anti-LFL2 antibodies disrupt tumor stroma integrity to reduce interstitial fluid pressure, thereby enhancing chemotherapy delivery while sparing normal tissues.

Anti-CLDN18.2 antibody IMAB362 overcomes limited efficacy of standard chemotherapy by targeting a broader patient population with high treatment coverage.

Administering an IL-16 antagonist addresses limited therapeutic options by reducing soluble collagen levels in bleomycin-induced lung damage.

Anti-DEspR antibodies inhibit angiogenesis and microvascular leakiness, preventing therapy-resistant tumor recurrence and hemorrhagic transformation in stroke.

IRS and Stat3 dual modulators resensitize resistant tumors to anti-PD-1 therapy by blocking survival signals that drive immune evasion.

Anti-AXL antibody-drug conjugate uses cleavable linker to release pyrrolobenzodiazepine warhead inside target cells, reducing systemic toxicity.

Engineered anti-Axl antibodies exploit acidic tumor pH for selective binding, resolving the trade-off between therapeutic efficacy and side-effects.

Pre-treatment CD14+ HLA-DRlow monocyte measurement identifies responsive patients, avoiding unnecessary exposure while ensuring clinical benefit.

Reduced neonatal Fc receptor binding in engineered antibodies minimizes radiation-induced toxicity while enabling higher therapeutic doses.

Anti-TIGIT antibody constructs bind specific epitopes to block inhibitory signaling, restoring T cell activation against tumors.

Engineered agonistic antibodies target human CD40 with specific affinity profiles that prevent cytokine release syndrome while maintaining antitumor efficacy.

Anti-NKG2A antibodies block the HLA-E escape mechanism in head and neck cancer, restoring NK cell cytotoxicity against tumor cells.

Humanized PD-1 nanobodies block tumor evasion through high-affinity antigen binding.

Antibodies form pores in cancer cell membranes to increase therapeutic uptake, reducing systemic toxicity and side effects.

Anti-podocalyxin antibodies bind specifically to podocalyxin, inhibiting tumor growth, metastasis, and vascularization in cancers overexpressing this protein.

Multispecific binding proteins recruit endogenous E3 ubiquitin ligases to direct cell surface proteins to lysosomes, bypassing PROTAC limitations.

Specific monoclonal antibodies quantify imatinib without cross-reactivity to N-desmethyl metabolites.

Site-specific cysteine insertion resolves ADC heterogeneity by directing cytotoxin attachment to defined light or heavy chain positions, reducing side effects.

Engineered binding agents target BTLA without blocking HVEM interaction, resolving autoimmune inflammation while preserving natural immune regulation.

Engineered antibodies use oxidized galactose residues to form stable oxime bonds with derivatized drugs for uniform payload attachment.

Segmented antibody libraries encode variable complementarity-determining regions within fixed framework structures to enhance binding affinity.

Combining recombinant poxvirus vaccines with TIM-3 antagonists overcomes immune checkpoint inhibition to reduce tumor volume and improve survival.

An IL-17RA antagonist treats psoriasis in patients who do not respond to anti-TNF-alpha antibodies by blocking specific cytokine receptors.

Non-fucosylated SEA-CD40 antibody overcomes immunologically cold uveal melanoma by enhancing immune activation potency.

Novel sulfonimidoylpurinone prodrugs activate Toll-like receptor 7 in the liver to induce cytokine release and improve survival rates.

Agonistic LTBR antibodies activate receptors to drive immune cell infiltration into solid tumors.

Radiopharmaceuticals combine with chemotherapy and immune inhibitors to improve survival in extensive stage small cell lung cancer.

Antibodies bind fibroblast growth factor receptor 1 to suppress cancer cell proliferation and inhibit tumor angiogenesis.

Administering immune checkpoint inhibitors based on M2 macrophage and NK cell levels to resolve treatment selection complexity.

Antibody binds AXL protein with high affinity to mediate internalization, resolving the trade-off between binding precision and development complexity.

Specific amino acid substitutions in the Fc region resist low pH denaturation and reduce glycosylation heterogeneity during manufacturing.

Adjuvant PD-1 inhibitor treatment suppresses tumor growth to reduce recurrence risk after surgery.

Engineered humanized anti-c-Met antibody targets c-Met signaling to overcome resistance from conventional EGFR or HER2 inhibitor therapies.

Neutralizing antibody binds YKL-40 and conjugates with metal chelators for targeted delivery.

Neutralizing antibodies targeting Dickkopf2 modulate the tumor immune microenvironment, restoring cytotoxic T cell function while reducing angiogenesis.

Segmented epitope targeting inhibits tumor growth by reducing Treg proliferation without broad immune modulation.

Isolated OX40 receptor binding molecules stimulate immune responses to enhance anti-tumor T cell function and inhibit tumor growth.

Methyleneamino group protects tubulysin acetate from hydrolysis, preserving biological activity.

GHR-targeting polypeptides reduce hepatocellular dysfunction and improve patient adherence by blocking growth hormone receptor activity.

Isomerized anti-BCMA antibodies resolve insufficient binding specificity by modifying CDR regions to target BCMA-mediated diseases.

Optimized heavy and light chain CDRs resolve binding affinity limits against B7-H3, enabling targeted tumor reduction in melanoma.

Antibodies targeting pre-BCR disrupt homo-dimerization and galectin binding, sparing mature B cells while eliminating precursor leukemia.

Anti-Siglec-9 IgM antibodies bind receptor targets to promote immune cell proliferation and activation.

Isolated monoclonal antibodies bind CD123 and CD3 to redirect T cells toward cancer cells.

Humanized R24 antibodies maintain binding affinity to the GD3 ganglioside antigen while reducing immunogenicity compared to murine versions.

A PD-L1 antibody stimulates T cell activation and proliferation through specific CDR regions.